TABLE 4.

Predictors of 10-yr Local Regional Recurrence Rates in Patients With Ductal Carcinoma In Situ Treated With Lumpectomy, With and Without Radiation Therapy

	Adjuvant Radiation Therapy			No Adjuvant Radiation Therapy
Predictor	Events/Total	10-Yr Local Regional Recurrence Rate	P Value	Events/Total	10-Yr Local Regional Recurrence Rate	P Value
All patients	33/1193	3.5% (2.4%, 5.1%)		28/298	6.7% (4.2%, 10.7%)
Age, yrs
≤40	5/72	10.0% (4.1%, 23.5%)	0.03	2/17	15.6% (4%, 50.7%)	0.26
>40	28/1121	3.0% (2%, 4.6%)		16/281	6.2% (3.8%, 10.2%)	—
Family history
No	15/662	2.4% (1.3%, 4.2%)	0.19	11/147	7.7% (4.2%, 13.9%)	0.35
Yes	18/530	4.9% (3%, 8.1%)		7/151	5.8% (2.8%, 12%)	—
First degree relative with breast cancer
No	28/979	3.4% (2.2%, 5.1%)	0.74	15/230	6.9% (4.1%, 11.5%)	0.54
Yes	5/213	3.9% (1.6%, 9.4%)		3/68	6.0% (1.9%, 18%)	—
Nuclear grade
Low or intermediate	17/592	3.8% (2.2%, 6.4%)	0.98	11/217	5.5% (3%, 10%)	0.19
High	16/579	3.2% (1.8%, 5.5%)		6/68	10.9% (4.9%, 23.4%)	—
Tumor size
≤1 cm	8/506	1.5% (0.7%, 3.2%)	0.055	10/164	6.5% (3.4%, 12.2%)	0.42
>1 cm	15/451	4.1% (2.3%, 7.3%)		4/51	10.6% (4.1%, 26.3%)	—
Comedo
Absent	26/789	2.6% (1.2%, 5.7%)	0.39	14/232	6.8% (4%, 11.5%)	0.62
Present	7/342	4.0% (2.6%, 6.3%)		4/51	8.3% (3.2%, 20.6%)	—
Necrosis
Absent	22/735	4.0% (2.6%, 6.3%)	0.8	16/213	8.0% (4.9%, 13%)	0.16
Present	11/443	2.4% (1.2%, 4.6%)		2/77	3.4% (0.8%, 13.4%)	—
Hormone therapy
No	20/600	4.3% (2.7%, 6.8%)	0.34	14/222	7.6% (4.5%, 12.7%)	0.65
Yes	13/593	2.6% (1.4%, 5%)		4/76	4.3% (1.4%, 12.8%)	—
Estrogen receptor status
Positive	13/704	2.3% (1.2%, 4.2%)	0.7	8/145	5.6% (2.7%, 11.4%)	0.98
Negative	2/138	1.5% (0.4%, 5.7%)		1/19	5.9% (0.9%, 35%)	—
Margin width
Free (≥2 mm)	31/1093	3.3% (2.2%, 4.9%)	0.69	14/278	5.4% (3.1%, 9.2%)	0.0006
Close (<2 mm)	2/100	4.8% (1.2%, 18.5%)		4/20	30.9% (12.4%, 64.6%)	—